前列康片在治疗Ⅲ型慢性前列腺炎患者中的效果及对血清炎症因子的影响

Effect of Qianliekang Tablet on Patients with Type Ⅲ CP and Its Effect on Serum Inflammatory Factors

目的探讨前列康片在治疗Ⅲ型慢性前列腺炎(CP)患者中的临床作用及对患者血清白细胞介素-2(IL-2)、IL-10及IL-1β水平的影响。方法选取我院收治的126例Ⅲ型CP患者,收集时间2016年4月至2017年5月,其中63例患者给予盐酸坦索罗新联合前列康片治疗(联合组)、另外63例患者给予盐酸坦索罗新治疗(对照组),对比两组患者治疗前后的最大尿流率(Qmax)、膀胱残余尿量(PVR)、前列腺体体积、前列腺移行区体积、血清IL-2、IL-10、IL-1β、美国国立卫生院慢性前列腺炎症状指数(NIH-CPSI)。结果治疗前,两组患者的NIH-CPSI评分差异无统计学意义(P>0. 05);治疗后,联合组患者的NIH-CPSI评分显著低于对照组,差异有统计学意义(P<0. 05);治疗前,两组患者的Qmax、PVR、前列腺体体积、前列腺移行区体积差异无统计学意义(P>0. 05);治疗后,联合组患者的PVR、前列腺体体积、前列腺移行区体积显著低于对照组,Qmax显著大于对照组,差异有统计学意义(P<0. 05);治疗前,两组患者血清IL-2、IL-10、IL-1β水平差异无统计学意义(P>0. 05);治疗后,联合组患者的血清IL-2、IL-10、IL-1β水平显著低于对照组,差异有统计学意义(P<0. 05)。结论Ⅲ型CP患者在使用盐酸坦索罗新治疗的同时加以前列康片,有利于进一步改善患者的临床症状、降低血清炎症反应、提高治疗效果。

Objective To investigate the clinical effects of Qianliekang tablets in the treatment of patients with type III chronic prostatitis( CP) and its effects on the serum levels of interleukin-2( IL-2),IL-10 and IL-1β.Methods 126 patients with type III CP admitted to our hospital from April 2016 to May 2017 were enrolled.63 patients were treated with tamsulosin hydrochloride combined with Qianliekang tablets( combined group),and another 63 patients were given tamsulosin hydrochloride( control group).The maximum urinary flow rate( Qmax),residual bladder volume( PVR),prostate volume,prostate transition zone volume,serum IL-2,IL-10,IL-1β and National Institutes of Health Chronic Prostatitis Symptom Index( NIH-CPSI) before and after treatment were compared between the two groups.Results Before treatment,there was no significant difference in NIH-CPSI score between the two groups( P>0. 05).After treatment,the NIH-CPSI score of the combined group was significantly lower than that of the control group,the difference was statistically significant( P < 0. 05). Before treatment,there was no significant difference in Qmax,PVR,prostatic volume,and prostate transition zone volume between the two groups( P> 0. 05). After treatment,the combined group had significantly lower PVR,prostate volume,and prostate transition zone volume. In the control group,Qmax was significantly higher than that in the control group,and the difference was statistically significant( P<0. 05).There was no significant difference in serum IL-2,IL-10 and IL-1β levels between the two groups before treatment( P> 0. 05). After treatment,the serum levels of IL-2,IL-10 and IL-1β in the combined group were significantly lower than those in the control group( P< 0. 05). Conclusion Patients with type Ⅲ CP who are treated with tamsulosin hydrochloride combined with Qianliekang Tablet are beneficial to improve clinical symptoms,reduce serum inflammatory response,and improve treatment effect.